Capricor Q1 net loss $33.9M ($0.59/share); Deramiocel BLA PDUFA Aug 22, 2026

CAPRICOR THERAPEUTICS, INC.

Net loss of $33.9M ($0.59/share) for Q1 2026 vs net loss of $24.4M ($0.53/share) in Q1 2025.
Cash balance of $278.6M as of March 31, 2026; expected to support operations through Q4 2027.
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected soon.
Filed suit against Nippon Shinyaku/NS Pharma citing flawed pricing in distribution agreement; seeking rescission and preliminary injunction.
New Chief Commercial Officer with direct DMD experience expected to join in coming weeks; eligible for Priority Review Voucher upon approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

today announced its financial results for the first quarter ended March 31, 2026

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-059380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.